Long-term treatment with Abbvie‘s adalimumab, sold as Humira, led to sustained clinical remission accompanied by better physical abilities…
Articles by Patricia Inacio PhD
An increase in disease activity during the early stages of axial spondyloarthritis (axSpA) is linked to a decline in…
Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab)Â led to fast, significant, and sustained symptom…
Two single variants in immune system-related genes may help predict ankylosing spondylitis with active disease response to therapy. The study…
Early disease onset and long disease duration may increase the risk of additional diseases in patients with ankylosing spondylitis, according…
Blood levels of a specific form of immunoglobulin G (IgG) antibodies may help diagnose ankylosing spondylitis (AS) with high…
Methotrexate alone or combined with therapies targeting the inflammatory tumor necrosis factor (TNF) may help improve the endothelium function –…
Novartis will present new four-year data from the MEASURE 1 study showing how Cosentyx (secukinumab) benefits patients with ankylosing…
The European Commission recently granted a marketing authorization for Imraldi, a biosimilar approved to treat the same…
A large-scale survey is underway for patients with a definite diagnosis of ankylosing spondylitis and who know their blood type.